Elizabeth Jungman

Elizabeth Jungman

  • Director
  • Public Health,
  • The Pew Charitable Trusts


Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse.

Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.

Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee and represents Pew as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.

Recent Work

View All
  • Drug Shortages

    National drug shortages, defined by the U.S. Food and Drug Administration (FDA) as a period of time when the demand or projected demand for a drug within the United States exceeds the supply of the drug, remain a complex and multilayered issue in the U.S. health care delivery system. Read More

  • How Market Forces Contribute to Drug Shortages

    When lifesaving medications go into shortage, the results can be fatal. Ensuring the continuity of the drug supply chain is therefore critical to public health. Quality issues, which can cause manufacturing lines to shut down or lose productivity, are cited as a primary contributor to shortages, but they are not the only forces at play. Read More

  • Pew Comments on FDA Draft Guidance Documents on Compounded Copies of Approved Drugs

    The Pew Charitable Trusts offered comments on draft guidance documents issued by the Food and Drug Administration in July 2016 regarding compounded drugs that are essentially copies of commercially available or approved drugs. The proposed guidance would preserve the FDA’s approval process, which is critical to protecting patient safety, while allowing important exceptions under limited,... Read More

Media Contact

Tami Holzman

Officer, Communications